Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages
Proceedings of the National Academy Sciences of the United States of America, 16 gennaio 2024

2) Analytical Ultracentrifugation Detects Quaternary Rearrangements and Antibody-Induced Conformational Selection of the SARS-CoV-2 Spike Trimer
International Journal of Molecular Sciences, 3 ottobre 2023

3) Adapting Neutralizing Antibodies to Viral Variants byStructure-Guided Affinity Maturation Using Phage DisplayTechnology
Global Challenges, 2023

4) Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
Nature Immunology, 6 marzo 2023

5) Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Cancer Cell, 22 febbraio 2023

6) Publisher Correction: Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Nature, settembre 2021

7) Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Science Immunology, 26 gennaio 2023

8) Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2
bioRxiv, 28 novembre 2022

9) A conformational switch controlling the toxicity of the prion protein
Nature Structural & Molecular Biology, agosto 2022

10) Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients
microorganisms, 10 giugno 2022

11) Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19
Nature Immunology, 27 maggio 2022

12) Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course
bioRxiv, 23 maggio 2022

13) Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Nature Communications, 13 maggio 2022

14) Immunity to SARS-CoV-2 up to 15 months after infection
iScience, 18 febbraio 2022

15) Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
Nature Immunology, febbraio 2022

16) Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies
Science Advances, 26 novembre 2021

17) Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
Clinical Microbiology and Infection, 25 settembre 2021

18) Humoral and cell-mediated response elicited by SARS-CoV-2 mRNA vaccine BNT162b2 e in healthcare workers: a longitudinal observational study
Clinical Microbiology Infection, 25 settembre 2021

19) Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction
Journal of Medical Chemistry, 23 settembre 2021

20) Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity
Nature Communications, 10 giugno 2021

21) Rational engineering of the lccβ T. versicolor laccase for the mediator-less oxidation of large polycyclic aromatic hydrocarbons
Computational and Structural Biotechnology Journal, 20 aprile 2021

22) Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Nature, 25 marzo 2021

23) SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Nature Communications, 11 marzo 2021

24) Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease
bioRxiv, 5 marzo 2021

25) Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease
bioRxiv, 22 gennaio 2021

26) Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity
Frontiers in Immunology, 20 novembre 2020
Luca Varani
is currently collaborating with
Istituto di Ricerca in Biomedicina (IRB) (Rif. IRB)
Via Francesco Chiesa 5
6500 Bellinzona
Luca Varani
on behalf of
Istituto di Ricerca in Biomedicina (IRB) USI (Rif. IRB)
is currently participating in the Research Group
Biologia Strutturale Computazionale
as Group Leader [Rif. 55110]
Luca Varani
is Head of Research Programs [Rif. 20700]
at Choose Life Biotech (Rif. CLB)
Via Pometta 1 6500 Bellinzona